xT CDx is an advanced genomic profiling solution used for comprehensive tumor and normal matched testing in oncology. With a focus on solid tumors, xT CDx leverages extensive gene coverage to aid in clinical decision-making. The system utilizes high-depth sequencing to provide actionable insights, aligning genomic findings with targeted therapy options. The platform is renowned for its substantial coverage of exons and is accredited for detecting a wide array of variants that contribute significantly to personalized medicine.
As an in vitro diagnostic system, xT CDx is designed to serve as a companion diagnostic tool for oncologists, particularly in tailoring treatments that align with existing therapeutic guidelines. Its sophisticated analytical capabilities ensure that oncologists have the support they need to match patient profiles with clinical trials and approved treatments promptly. This facilitates a genomic-centric approach, integrating DNA sequencing insights into the broader clinical workflow.
Incorporating both tumor and normal tissue comparisons, xT CDx is able to discern hereditary traits that might influence cancer treatment. This dual-approach testing enhances the diagnosis accuracy and optimizes treatment pathways, setting a new standard in oncology precision testing.
